Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 14,400 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Trading Up 0.2 %

NYSE:EW opened at $85.24 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm has a market capitalization of $51.37 billion, a price-to-earnings ratio of 36.74, a price-to-earnings-growth ratio of 3.55 and a beta of 1.10. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The business has a fifty day moving average price of $90.13 and a 200-day moving average price of $79.23.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on EW shares. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Stifel Nicolaus raised their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Citigroup lifted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Finally, Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Nordea Investment Management AB boosted its holdings in Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after buying an additional 1,488,791 shares during the period. Telos Capital Management Inc. boosted its holdings in Edwards Lifesciences by 158.2% in the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after buying an additional 56,000 shares during the period. Arlington Trust Co LLC boosted its holdings in Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after buying an additional 12,069 shares during the period. Versor Investments LP boosted its holdings in Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after buying an additional 2,043 shares during the period. Finally, HealthInvest Partners AB bought a new position in Edwards Lifesciences in the 4th quarter worth $1,587,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.